Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00711555 · ClinicalTrials.gov registry record · Phase 2
Emend for Multiple-day Emetogenic Chemotherapy
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00711555 is a Phase 2 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 22 participants.
The verdict
NCT00711555, a Phase 2 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effect of Emend (aprepitant) on nausea and vomiting associated with chemotherapy. Chemotherapy commonly causes nausea and vomiting and this affects patients' quality of life and attitudes toward treatment. Although nausea and vomiting associated with chemotherapy has been decreasing due to improved therapy, some patients will still experience this side effect. Therefore, new medications are needed to decrease the amount of nausea and vomiting patients have with chemotherapy. Emend (aprepitant) is a new medication used to treat nausea and vomiting with chemotherapy, but it has only been studied in patients receiving only one dose of chemotherapy that makes most people sick. However, there is little experience with this medication in patients receiving multiple days of chemotherapy that causes nausea and vomiting.
Interventions
- DRUG aprepitant, ondansetron, dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2005-11 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00711555
The ClinicalTrials.gov registry entry for NCT00711555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aprepitant, ondansetron, dexamethasone is the first listed.
NCT00711555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00711555 about?
NCT00711555 is a clinical study titled "Emend for Multiple-day Emetogenic Chemotherapy". The purpose of the study is to assess the effect of Emend (aprepitant) on nausea and vomiting associated with chemotherapy. Chemotherapy commonly causes nausea and vomiting and this affects patients' quality of life and attitudes toward treatment. Although nausea and vomiting associated with chemoth...
What is the current status of trial NCT00711555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2005-11. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00711555?
The interventions under investigation include: aprepitant, ondansetron, dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00711555?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.